A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

NCT04081337 · Completed

Last updated 2026-05-28

This clinical trial is testing how tirzepatide affects energy use and food intake in adults with obesity over an 18-week period.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 55 people

Who can join Ages 18–60 · all sexes

Timeline Started 2020-07 · est. completion 2022-05

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT04081337 ↗

Description as written by the study sponsor.

This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat. The study lasted for 28 weeks and will include about 21 visits to the study center.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Change From Baseline to Week 18 in Sleep Metabolic Rate (SMR)
Sponsor	Eli Lilly and Company
Conditions studied	Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04081337 ↗